Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6611097 | 0.90 | MEN1 (0.45) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL3271284 | 0.83 | SIGMAR1 (0.48) | LMNAMAPK1ALDH1A1SIGMAR1HTT | |
| SCHEMBL7996238 | 0.83 | MEN1 (0.49) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL14044084 | 0.83 | MEN1 (0.49) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL4716094 | 0.83 | MEN1 (0.53) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL172685 | 0.81 | MEN1 (0.47) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL14463410 | 0.81 | MEN1 (0.47) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL20353189 | 0.80 | SIGMAR1 (0.54) | MEN1KMT2ALMNAMAPTADRA2C | |
| SCHEMBL13995949 | 0.79 | ALDH1A1 (0.62) | MEN1KMT2ALMNAMAPTMAPK1 | |
| SCHEMBL13995887 | 0.79 | ALDH1A1 (0.62) | MEN1KMT2ALMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325547-A1 | ANTI-SARS-COV-2 DRUG | KAGOSHIMA UNIVERSITY (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4431151-A1 | ANTI-SARS-COV-2 DRUG | Kagoshima University (JP) | 2024-09-18 | — | — | EP | disclosed |
| CN-118302413-A | Anti-SARS-CoV-2 medicine | 国立大学法人鹿儿岛大学 | 2024-07-05 | — | — | CN | disclosed |
| EP-4370207-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | Nido Biosciences, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11858945-B2 | Alkyne-containing antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2023-11-21 | — | — | US | disclosed |
| EP-4268824-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Manros Therapeutics (FR) | 2023-11-01 | — | — | EP | disclosed |
| US-7189728-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING, BV (NL) | 2007-03-13 | — | — | US | disclosed |
| US-7179835-B2 | 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2007-02-20 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1544200-A1 | 1,2,4 -TRIAZOLO 1,5-c PYRIMIDINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-06-22 | — | — | EP | disclosed |
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-01-06 | — | — | US | disclosed |
| EP-1324985-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2004-10-06 | — | — | EP | disclosed |
| EP-1324985-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002028831-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820767-B2 | Benzyl amine-containing heterocyclic compounds and compositions useful against mycobacterial infection | BET1, BRD4, BRD3 | MEN1 1572/4885KMT2A 1812/4885LMNA 1620/4885 |
| US-20050004119-A1 | 2-(3-Sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors | SERPINC1, F11, SERPINE1 | MEN1 1263/4885KMT2A 2682/4885LMNA 358/4885 |
| US-20060058320-A1 | [1,2,4] Triazolo[1,5-c]pyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | MEN1 3652/4885KMT2A 1987/4885LMNA 4026/4885 |
| US-20070004695-A1 | THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL PHENOXY SUBSTITUTED PROPYL DERIVATIVES USEFUL AS D4 ANTAGONISTS | DRD4, DRD2, SLC6A3 | MEN1 4878/4885KMT2A 2395/4885LMNA 4884/4885 |
| US-11912714-B2 | Spiropyrrolidine derived antiviral agents | ACE, ACE2, PKD1 | MEN1 3064/4885KMT2A 4262/4885LMNA 3483/4885 |
| US-11858945-B2 | Alkyne-containing antiviral agents | ACE, SARS1, ACE2 | MEN1 4315/4885KMT2A 3482/4885LMNA 3321/4885 |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | BTK, SYK, LCK | MEN1 1463/4885KMT2A 1815/4885LMNA 3836/4885 |
| US-20250325547-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, AGTR2 | MEN1 1894/4885KMT2A 2294/4885LMNA 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.